News
LSTA
3.600
+2.86%
0.100
Lisata Therapeutics Q3 EPS $(7.88) Down From $(1.74) YoY
Benzinga · 11/10 22:11
Lisata Therapeutics GAAP EPS of -$7.88 misses by $6.61
Seekingalpha · 11/10 21:19
-- Earnings Flash (LSTA) LISATA THERAPEUTICS Reports Q3 Loss $-7.88
-- Earnings Flash (LSTA) LISATA THERAPEUTICS Reports Q3 Loss $-7.88
MT Newswires · 11/10 16:33
Notable earnings after Thursday's close
Seekingalpha · 11/09 22:35
Lisata Therapeutics Announces Participation in Upcoming Conferences in November 2022
BASKING RIDGE, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other seriou...
GlobeNewswire · 11/07 13:00
Lisata Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022, at 4:30 p.m. Eastern Time
BASKING RIDGE, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other seriou...
GlobeNewswire · 11/03 12:00
HC Wainwright & Co. Maintains Buy on Lisata Therapeutics, Raises Price Target to $15
HC Wainwright & Co. analyst Joseph Pantginis maintains Lisata Therapeutics (NASDAQ:LSTA) with a Buy and raises the price target from $6 to $15.
Benzinga · 10/19 10:59
--HC Wainwright Adjusts Lisata Therapeutics' Price Target to $15 From $6, Keeps Buy Rating
--HC Wainwright Adjusts Lisata Therapeutics' Price Target to $15 From $6, Keeps Buy Rating
MT Newswires · 10/19 08:25
Lisata Therapeutics Announces Participation in Upcoming Conferences in October 2022
BASKING RIDGE, N.J., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other ser...
GlobeNewswire · 10/06 12:30
Lisata Therapeutics’ Director and Scientific Founder of the CendR Platform™ Technology, Erkki Ruoslahti, M.D., Ph.D., Receives 2022 Albert Lasker Basic Medical Research Award
BASKING RIDGE, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other se...
GlobeNewswire · 09/29 12:00
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
Benzinga · 09/19 05:53
12 Health Care Stocks Moving In Friday's Intraday Session
 
Benzinga · 09/16 18:06
Why NCR Is Trading Lower By Around 23%, Here Are 42 Stocks Moving In Friday's Mid-Day Session
Gainers Kensington Capital Acquisition Corp. IV (NYSE: AMPX) jumped 35.4% to $13.54 after gaining 11% on Thursday.
Benzinga · 09/16 16:38
Life Sciences Virtual Investor Conference: Presentations Now Available for On-Demand Viewing
NEW YORK, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the September Life Sciences Virtual Investor Conference are now available for on-dema...
GlobeNewswire · 09/16 12:35
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA” Lisata has approximately $76 million in cash and investments following transaction close Lisata strengthens Board of Directors and Executive Leadership Team, appointing sea...
GlobeNewswire · 09/15 13:15
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Benzinga · 09/14 17:33
Why SciSparc Is Trading Higher By 68%, Here Are 48 Stocks Moving In Wednesday's Mid-Day Session
Gainers Akerna Corp. (NASDAQ: KERN) shares rose 81.2% to $0.2355 after gaining 8% on Tuesday.
Benzinga · 09/14 16:28
Caladrius rallies on approval of merger, name change to Lisata Therapeutics
Caladrius Biosciences (NASDAQ:CLBS) <a href="https://seeking...
Seekingalpha · 09/14 12:24
Caladrius Biosciences Secures Shareholder Approval for Cend Therapeutics Merger
Caladrius Biosciences Secures Shareholder Approval for Cend Therapeutics Merger
MT Newswires · 09/14 10:33
Caladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022
BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announ...
GlobeNewswire · 09/08 12:00
More
Webull provides a variety of real-time LSTA stock news. You can receive the latest news about Lisata Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About LSTA
Lisata Therapeutics, Inc., formerly Caladrius Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The Company focuses primarily on advancing its CendR Platform technology product candidates in a range of oncology indications. Its lead investigational product candidate, LSTA1, is designed to modify the tumor microenvironment by activating an uptake pathway that allows anti-cancer drugs to penetrate solid tumors. LSTA1 actuates an active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. In addition, the Company also has clinical development programs based on its autologous CD34+ cell therapy technology platform.